001     310004
005     20260223120901.0
024 7 _ |a 10.1016/j.ijrobp.2026.01.031
|2 doi
024 7 _ |a pmid:41720170
|2 pmid
024 7 _ |a 0360-3016
|2 ISSN
024 7 _ |a 1879-355X
|2 ISSN
037 _ _ |a DKFZ-2026-00417
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Reuter, Lukas M
|b 0
245 _ _ |a Prediction of Symptomatic Radiation Pneumonitis in Lung Cancer Patients: A Radiomics and Dosiomics Machine Learning Approach Using the Prospective Multicenter RTOG 0617 and REQUITE trials.
260 _ _ |a Amsterdam [u.a.]
|c 2026
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1771842434_3895552
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a epub
520 _ _ |a Radiation-induced pneumonitis (RP) is a side effect after thoracic radiotherapy (RT). The ability to predict RP would facilitate treatment modifications. This study investigates the predictive capacity for symptomatic RP (CTCAE≥2) employing Radiomics and Dosiomics models.Computed tomography (CT) scans, along with physical and 2-Gy equivalent dose volumes (EQD2), dose-volume histograms (DVH), and clinical parameters, were evaluated for 708 multicenter lung cancer patients, among whom 89 developed RP≥2. The training cohort consisted of 441 patients from the prospective RTOG 0617 trial. External validation was carried out on 267 patients from the prospective REQUITE study. A Random Forest classifier was employed, with feature selection executed within the inner loop of a 10x5-fold nested cross-validation (nCV) utilizing the minimum-redundancy-maximum-relevance algorithm. To address class imbalances, synthetic oversampling and undersampling were implemented using SMOTE-Tomek. The QUANTEC Normal Tissue Complication Probability (NTCP) model served as a reference. Additionally, the experiments were stratified by subgroups (standard/high-dose and 3D-conformal RT (3D-CRT)/intensity-modulated RT (IMRT)).The best radiomics model identified in the nCV was trained on the standard-dose subgroup achieved a test ROC-AUC of 0.56. The baseline NTCP model showed a predictive performance with a ROC-AUC of 0.56, which was largely dependent on radiation technique (ROC-AUCS: 3D-CRT: 0.75, IMRT: 0.50). The DosiomicsEQD2 model, trained on the full training cohort, attained the second-best performance in the nCV, demonstrating the same technique-dependence (ROC-AUC of 0.75 vs. 0.39). Using a DosiomicsEQD2 ensemble model trained separately on 3D-CRT and IMRT subgroups increased overall performance to a testing ROC-AUC of 0.61, outperforming other modeling strategies for IMRT, while being outperformed by clinical models for 3D-CRT.This prospective trial-based study reveals an overall limited predictive capacity of radiomics and dosiomics models and a large influence of radiation technique. IMRT-specific models should be investigated further.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Dosiomics
|2 Other
650 _ 7 |a Lung Cancer
|2 Other
650 _ 7 |a NTCP
|2 Other
650 _ 7 |a Radiation pneumonitis
|2 Other
650 _ 7 |a Radiomics
|2 Other
650 _ 7 |a Side Effects
|2 Other
700 1 _ |a Kraus, Kim
|0 P:(DE-He78)6e9779a1e058ccda2d6443c44474cc3b
|b 1
700 1 _ |a Fischer, Stefan M
|b 2
700 1 _ |a Pletzer, Danai
|b 3
700 1 _ |a Bernhardt, Denise
|b 4
700 1 _ |a Combs, Stephanie E
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Schnabel, Julia A
|b 6
700 1 _ |a Peeken, Jan C
|0 P:(DE-HGF)0
|b 7
773 _ _ |a 10.1016/j.ijrobp.2026.01.031
|g p. S0360301626003652
|0 PERI:(DE-600)1500486-7
|p nn
|t International journal of radiation oncology, biology, physics
|v nn
|y 2026
|x 0360-3016
909 C O |o oai:inrepo02.dkfz.de:310004
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)6e9779a1e058ccda2d6443c44474cc3b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2026
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-11-06
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J RADIAT ONCOL : 2022
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-11-06
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-06
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-11-06
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J RADIAT ONCOL : 2022
|d 2025-11-06
920 1 _ |0 I:(DE-He78)MU01-20160331
|k MU01
|l DKTK Koordinierungsstelle München
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)MU01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21